The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.
|Number of pages||8|
|Journal||Drug Discovery Today: Disease Models|
|Publication status||Published - 2016 Feb 2|
Bibliographical noteFunding Information:
This research was supported by a grant ( 14182MFDS978 ) from Korea Food and Drug Administration in 2015; the National Research Foundation of Korea (NRF) funded by the MEST ( 2015R1A2A1A01003845 ); and a Korean Healthcare Technology R&D Project from the Ministry of Health and Welfare ( A085136 ).
© 2017 The Author(s)
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Drug Discovery